miR-376b and miR-4668 predict therapeutic response to sunitinib
in metastatic renal cell carcinoma

a 2019

miR-376b and miR-4668 predict therapeutic response to sunitinib in metastatic renal cell carcinoma

BOHOŠOVÁ, Júlia, Jaroslav JURÁČEK, Alexandr POPRACH, T. BUCHLER, O. FIALA et. al.

Základní údaje

Originální název

miR-376b and miR-4668 predict therapeutic response to sunitinib in metastatic renal cell carcinoma

Autoři

BOHOŠOVÁ, Júlia (703 Slovensko, domácí), Jaroslav JURÁČEK (203 Česká republika, domácí), Alexandr POPRACH (203 Česká republika, domácí), T. BUCHLER, O. FIALA, Lenka RADOVÁ (203 Česká republika, domácí), Marek SVOBODA (203 Česká republika, domácí), Alena KOPKOVÁ (203 Česká republika, domácí), Marek VEČEŘA (703 Slovensko, domácí) a Ondřej SLABÝ (203 Česká republika, garant, domácí)

Vydání

AACR Annual Meeting on Bioinformatics, Convergence Science, and Systems Biology, 2019

Další údaje

Jazyk

angličtina

Typ výsledku

Konferenční abstrakt

Obor

30204 Oncology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 9.727

Kód RIV

RIV/00216224:14740/19:00108622

Organizační jednotka

Středoevropský technologický institut

ISSN

DOI

http://dx.doi.org/10.1158/1538-7445.AM2019-1800

UT WoS

000488129904321

Klíčová slova anglicky

miR-376b; miR-4668

Štítky

rivok

Příznaky

Mezinárodní význam

Změněno: 3. 4. 2020 20:01, Mgr. Pavla Foltynová, Ph.D.

Anotace

V originále

Metastatic renal cell carcinoma (mRCC) is routinely treated with sunitinib, a tyrosine kinase inhibitor (TKI) of VEGF signalisation. Although disease eventually progresses in most mRCC patients, length of progression-free survival (PFS) is ranging from few weeks up to more than 24 months. Patients with initial resistance to sunitinib could be redirected to other therapeutical options, as there are several other TKIs available for use in second and third line. However, without a reliable biomarker no result can be predicted. MicroRNAs (miRNAs) belong to class of short non-coding RNAs and could serve as biomarkers of therapy response due to their unique character and presence in tissues and body fluids. Their biomarker potential has been discussed concerning many diseases including mRCC, but current knowledge is very weak, has several discrepancies and is acquired on relatively small cohorts.

Návaznosti

NV18-03-00554, projekt VaV

Název: Molekulární klasifikace renálního buněčného karcinomu založená na expresi dlouhých nekódujících RNA a její využití v diagnostice, předpovědi prognózy a terapii

Investor: Ministerstvo zdravotnictví ČR, Molecular classification of renal cell carcinoma based on long noncoding RNAs expression and its implication for diagnosis, prognosis and therapy

Citovat

BOHOŠOVÁ, Júlia, Jaroslav JURÁČEK, Alexandr POPRACH, T. BUCHLER, O. FIALA, Lenka RADOVÁ, Marek SVOBODA, Alena KOPKOVÁ, Marek VEČEŘA a Ondřej SLABÝ. miR-376b and miR-4668 predict therapeutic response to sunitinib in metastatic renal cell carcinoma. In AACR Annual Meeting on Bioinformatics, Convergence Science, and Systems Biology. 2019. ISSN 0008-5472. Dostupné z: https://dx.doi.org/10.1158/1538-7445.AM2019-1800.

@proceedings{1642624,
   author = {Bohošová, Júlia and Juráček, Jaroslav and Poprach, Alexandr and Buchler, T. and Fiala, O. and Radová, Lenka and Svoboda, Marek and Kopková, Alena and Večeřa, Marek and Slabý, Ondřej},
   booktitle = {AACR Annual Meeting on Bioinformatics, Convergence Science, and Systems Biology},
   doi = {http://dx.doi.org/10.1158/1538-7445.AM2019-1800},
   keywords = {miR-376b; miR-4668},
   language = {eng},
   title = {miR-376b and miR-4668 predict therapeutic response to sunitinib in metastatic renal cell carcinoma},
   year = {2019}
}

TY  - CONF
ID  - 1642624
AU  - Bohošová, Júlia - Juráček, Jaroslav - Poprach, Alexandr - Buchler, T. - Fiala, O. - Radová, Lenka - Svoboda, Marek - Kopková, Alena - Večeřa, Marek - Slabý, Ondřej
PY  - 2019
TI  - miR-376b and miR-4668 predict therapeutic response to sunitinib in metastatic renal cell carcinoma
KW  - miR-376b
KW  - miR-4668
N2  - Metastatic renal cell carcinoma (mRCC) is routinely treated with sunitinib, a tyrosine kinase inhibitor (TKI) of VEGF signalisation. Although disease eventually progresses in most mRCC patients, length of progression-free survival (PFS) is ranging from few weeks up to more than 24 months. Patients with initial resistance to sunitinib could be redirected to other therapeutical options, as there are several other TKIs available for use in second and third line. However, without a reliable biomarker no result can be predicted. MicroRNAs (miRNAs) belong to class of short non-coding RNAs and could serve as biomarkers of therapy response due to their unique character and presence in tissues and body fluids. Their biomarker potential has been discussed concerning many diseases including mRCC, but current knowledge is very weak, has several discrepancies and is acquired on relatively small cohorts.
ER  -

BOHOŠOVÁ, Júlia, Jaroslav JURÁČEK, Alexandr POPRACH, T. BUCHLER, O. FIALA, Lenka RADOVÁ, Marek SVOBODA, Alena KOPKOVÁ, Marek VEČEŘA a Ondřej SLABÝ. miR-376b and miR-4668 predict therapeutic response to sunitinib in metastatic renal cell carcinoma. In \textit{AACR Annual Meeting on Bioinformatics, Convergence Science, and Systems Biology}. 2019. ISSN~0008-5472. Dostupné z: https://dx.doi.org/10.1158/1538-7445.AM2019-1800.

Podrobný výpis o publikaci